Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.

摘要: Thiazolidine derivatives are newly developed insulin sensitizer agents that act to lower plasma glucose and reduce hyperinsulinemia (1), they being used treat patients with type 2 diabetes accompanying resistance. However, the precise molecular mechanism by which thiazolidines counteract general resistance has yet be clarified. Glucocorticoid induces gluconeogenesis resistance, resulting in development of (2), but mechanisms remain elucidated. Recent studies showed troglitazone, was first clinically applied drug thiazolidine derivatives, improved dexamethasone (DXM)-induced rats a clamp study (3) it had good effect on glucocorticoid-induced (4). In present study, we examined effects troglitazone pioglitazone, another sensitizer, induced short-term DXM treatment, compared their those metformin. Furthermore, been reported concentration oral contraceptives ethinylestradiol norethindrone, metabolized liver enzyme CYP3A4 (5). Troglitazone is also believed an inducer like rifampicin phenytoin, speculated may glucocorticoid, CYP3A4, enhancing activity CYP3A4. this investigated pioglitazone …